MedTrace Logo

Metformin Use in Chronic Kidney Disease: The CKD-Met Study

NCT02844153 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2016-07-26

No results posted yet for this study

Summary

Metformin is the most widely prescribed oral treatment for diabetes, and the only one that showed a survival benefit.

Yet, there is no consensus on the optimal dose and withdrawal of metformin in chronic kidney disease (CKD) patients.

The aim of the study is to describe the use and side-effects of metformin in CKD patients in routine practice.

Conditions

Interventions

OTHER

modalities of metformin prescription

Metformin prescription or not, in each CKD stage

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Denis FOUQUE, MD PhD · Claude Bernard University, Lyon, France, Lyon Sud university hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2018-03-31
Completion
2020-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02844153 on ClinicalTrials.gov